Effects of Proton Pump Inhibitors in Asthmatics with Gastroesophageal Reflux Disease.
10.4166/kjg.2011.58.4.178
- Author:
Yun Bin LEE
1
;
Joo Hyun LIM
;
Yoon Jin CHOI
;
Ji Yeon KIM
;
Jun Hyuk SON
;
Sun Mi CHOI
;
Hyun Jin JO
;
Cheol Min SHIN
;
Sang Hyup LEE
;
Young Soo PARK
;
Jin Hyeok HWANG
;
Jin Wook KIM
;
Sook Hyang JEONG
;
Nayoung KIM
;
Dong Ho LEE
;
Hyun Chae JUNG
;
In Sung SONG
Author Information
1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. dhljohn@snubh.org
- Publication Type:Original Article ; English Abstract
- Keywords:
Asthma;
Gastroesophageal reflux;
Proton pump inhibitors;
Peak expiratory flow rate
- MeSH:
Adrenergic beta-Agonists/therapeutic use;
Adult;
Aged;
Asthma/*complications/drug therapy;
Female;
Follow-Up Studies;
Gastroesophageal Reflux/complications/*drug therapy;
Gastroscopy;
Glucocorticoids/therapeutic use;
Humans;
Male;
Middle Aged;
Peak Expiratory Flow Rate;
Proton Pump Inhibitors/*therapeutic use;
Treatment Outcome
- From:The Korean Journal of Gastroenterology
2011;58(4):178-183
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Gastroesophageal reflux disease (GERD) is common in asthma patients. Proton pump inhibitor (PPI) therapy improves symptoms of asthma in some patients. The objective of this study was to investigate endoscopic findings of GERD in asthma patients and to assess the effect of gastric acid suppression with the PPIs on symptom improvement and pulmonary function. METHODS: From 105 consecutive patients with GERD symptoms during follow up for asthma, 45 patients were enrolled. Patients enrolled to this study were asked about GERD symptoms before and after treating with PPI. Endoscopic findings were described according to Los Angeles classification. The improvement of asthma symptoms and follow-up pulmonary function test were investigated after administration of PPIs. RESULTS: Esophageal symptoms such as heartburn and acid reflux were present in 25 patients (55.6%), and patients without esophageal symptoms were 20 (44.4%). The degree of endoscopic abnormality was not significantly different between groups with or without esophageal symptoms. The improvement of symptoms was seen in 44 patients (97.8%) except 1 patient after administration of PPIs. The number of patients classified to the low-dose group was 7 patients (15.6%) and that of patients classified to the standard-dose group was 38 patients (84.4%). The follow-up pulmonary function test, peak expiratory flow rate (L/sec) was improved in 3 patients (3 of 7, 42.9%) of the low-dose group, and in 24 patients (24 of 38, 63.2%) of the standard-dose group. The improvement of ventilatory function was not significantly different according to dose of PPIs. CONCLUSIONS: Treatment with PPIs is expected to improve subjective symptoms and ventilatory function in asthma patients.
